Table 4. The stratified analysis between rs2275913/rs763780 polymorphisms and clinical characteristics of CRC patients.
| Characteristics | Genotype distributions | |||
|---|---|---|---|---|
| rs2275913 | GG | GA | AA | GA+AA |
| Histological grade | ||||
| MD/WD | 130/16 | 117/15 | 27/3 | 144/18 |
| OR (95%CI); P-value | 1.0 (reference) | 0.96 (0.46–2.03); 0.915 | 1.11 (0.30–4.07); 0.877 | 0.99 (0.48–2.01); 0.966 |
| Histological grade | ||||
| PD/WD | 14/16 | 22/15 | 7/3 | 29/18 |
| OR (95%CI); P-value | 1.0 (reference) | 1.68 (0.63–4.43); 0.296 | 2.67 (0.58–12.33); 0.201 | 1.84 (0.73–4.66); 0.195 |
| TNM stage | ||||
| III+IV/I+II | 70/90 | 86/68 | 23/14 | 109/82 |
| OR (95%CI); P-value | 1.0 (reference) | 1.63 (1.04–2.54); 0.032 | 2.11 (1.01–4.40); 0.043 | 1.71 (1.12–2.61); 0.013 |
| Tumor size | ||||
| >5 cm/≤5 cm | 99/61 | 82/72 | 21/16 | 103/88 |
| OR (95%CI); P-value | 1.0 (reference) | 0.70 (0.45–1.10); 0.122 | 0.81 (0.39–1.67); 0.565 | 0.72 (0.47–1.11); 0.133 |
| Lymph node metastasis | ||||
| Yes/No | 63/97 | 80/74 | 22/15 | 102/89 |
| OR (95%CI); P-value | 1.0 (reference) | 1.67 (1.06–2.61); 0.025 | 2.26 (1.09–4.68); 0.026 | 1.77 (1.15–2.70); 0.009 |
| Family history | ||||
| Yes/No | 24/136 | 17/137 | 6/31 | 23/168 |
| OR (95%CI); P-value | 1.0 (reference) | 0.70 (0.36–1.37); 0.298 | 1.10 (0.41–2.91); 0.853 | 0.78 (0.42–1.44); 0.418 |
| Histology | ||||
| Adenocarcinoma/Not | 155/5 | 149/5 | 33/4 | 182/9 |
| OR (95%CI); P-value | 1.0 (reference) | 0.96 (0.27–3.39); 0.951 | 0.27 (0.07–1.05); 0.058 | 0.65 (0.21–1.99); 0.452 |
| ESR | ||||
| ≥10/<10 | 63/97 | 68/86 | 17/20 | 85/106 |
| OR (95%CI); P-value | 1.0 (reference) | 1.22 (0.78–1.91); 0.391 | 1.31 (0.64–2.69); 0.464 | 1.24 (0.81–1.89); 0.333 |
| CRP | ||||
| ≥25/<25 | 13/147 | 9/145 | 7/30 | 16/175 |
| OR (95%CI); P-value | 1.0 (reference) | 0.70 (0.29–1.69); 0.431 | 2.64 (0.97–7.17); 0.057 | 1.03 (0.48–2.22); 0.932 |
| rs763780 | TT | TC | CC | TC+CC |
|---|---|---|---|---|
| Histological grade | ||||
| MD/WD | 187/23 | 77/11 | 9/1 | 87/11 |
| OR (95%CI); P-value | 1.0 (reference) | 0.86 (0.40–1.85); 0.701 | 0.49 (0.10–2.46); 0.378 | 0.97 (0.45–2.09); 0.943 |
| Histological grade | ||||
| PD/WD | 31/23 | 12/11 | 0/0 | 12/11 |
| OR (95%CI); P-value | 1.0 (reference) | 0.81 (0.30–2.16); 0.672 | NA | 0.81 (0.30–2.16); 0.672 |
| TNM stage | ||||
| III+IV/I+II | 116/125 | 39/61 | 5/5 | 44/66 |
| OR (95%CI); P-value | 1.0 (reference) | 0.69 (0.43–1.11); 0.123 | 1.08 (0.30–3.82); 0.908 | 0.72 (0.46–1.14); 0.156 |
| Tumor size | ||||
| >5 cm/≤5 cm | 135/106 | 60/40 | 7/3 | 67/43 |
| OR (95%CI); P-value | 1.0 (reference) | 1.18 (0.73–1.89); 0.499 | 1.83 (0.46–7.26); 0.382 | 1.22 (0.77–1.94); 0.390 |
| Lymph node metastasis | ||||
| Yes/No | 86/155 | 31/69 | 5/5 | 36/74 |
| OR (95%CI); P-value | 1.0 (reference) | 0.81 (0.49–1.33); 0.407 | 1.80 (0.51–6.40); 0.356 | 0.88 (0.54–1.41); 0.589 |
| Family history | ||||
| Yes/No | 32/209 | 15/85 | 1/9 | 15/95 |
| OR (95%CI); P-value | 1.0 (reference) | 1.15 (0.59–2.24); 0.675 | 0.73 (0.09–5.92); 0.764 | 1.03 (0.53–1.99); 0.927 |
| Histology | ||||
| Adenocarcinoma/Not | 231/10 | 96/4 | 9/1 | 105/5 |
| OR (95%CI); P-value | 1.0 (reference) | 1.04 (0.32–3.39); 0.950 | 0.39 (0.05–3.38); 0.393 | 0.91 (0.30–2.73); 0.865 |
| ESR | ||||
| ≥10/<10 | 100/141 | 37/63 | 2/8 | 39/71 |
| OR (95%CI); P-value | 1.0 (reference) | 0.83 (0.51–1.34); 0.441 | 0.35 (0.07–1.70); 0.193 | 0.78 (0.49–1.24); 0.284 |
| CRP | ||||
| ≥25/<25 | 12/229 | 6/94 | 1/9 | 7/103 |
| OR (95%CI); P-value | 1.0 (reference) | 1.22 (0.44–3.34); 0.802 | 2.12 (0.25–18.13); 0.492 | 1.30 (0.50–3.39); 0.596 |
Bold values are statistically significant (P < 0.05). PD, poorly differentiation, MD, moderately differentiation, WD, well differentiation; TNM, tumor node metastasis.